Credit Suisse Upgrades PTC Therapeutics (PTCT) to Outperform; ROW Translarna Sales Risk Off the Table

November 14, 2016 6:18 AM EST
Get Alerts PTCT Hot Sheet
Price: $15.47 --0%

Rating Summary:
    4 Buy, 8 Hold, 0 Sell

Rating Trend: = Flat

Today's Overall Ratings:
    Up: 0 | Down: 0 | New: 0
Trade PTCT Now!
Join SI Premium – FREE

Get daily under-the-radar research with's Stealth Growth Insider Get your 2-Wk Free Trial here.

Credit Suisse upgraded PTC Therapeutics (NASDAQ: PTCT) from Neutral to Outperform with a price target of $25.00 (from $15.00), saying they believe much of the near-term risk associated with ROW Translarna sales are off the table.

Analyst Alethia Young commented, "PTC announced this morning that CHMP is maintaining their conditional marketing approval in Europe. We have increased our probability of success in their ROW revenue stream to 100%. We had previously assumed a 75% probability of success. They also announced design of post marketing trial in Europe which is a 3-year study with data expected in 1Q 2021. We expect that approval would be reviewed again when this data reads out. Therefore we would expect the company can sell Translarna for at least another four years with no disruption. Our focus now turns to commercial execution of Translarna sales in the EU/RoW where DMD has high unmet need and Translarna is the only approved therapy."

For an analyst ratings summary and ratings history on PTC Therapeutics click here. For more ratings news on PTC Therapeutics click here.

Shares of PTC Therapeutics closed at $11.30 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, Hot Upgrades, Upgrades

Related Entities

Credit Suisse

Add Your Comment